高级搜索

结直肠癌中microRNA标志物临床诊断价值的研究进展

裴傲秋, 罗 茂, 何晓彬

裴傲秋, 罗 茂, 何晓彬. 结直肠癌中microRNA标志物临床诊断价值的研究进展[J]. 肿瘤防治研究, 2014, 41(07): 839-843. DOI: 10.3971/j.issn.1000-8578.2014.07.033
引用本文: 裴傲秋, 罗 茂, 何晓彬. 结直肠癌中microRNA标志物临床诊断价值的研究进展[J]. 肿瘤防治研究, 2014, 41(07): 839-843. DOI: 10.3971/j.issn.1000-8578.2014.07.033
PEI Aoqiu, LUO Mao, HE Xiaobin. Recent Progress of microRNA as Colorectal Cancer Clinical Biomarker[J]. Cancer Research on Prevention and Treatment, 2014, 41(07): 839-843. DOI: 10.3971/j.issn.1000-8578.2014.07.033
Citation: PEI Aoqiu, LUO Mao, HE Xiaobin. Recent Progress of microRNA as Colorectal Cancer Clinical Biomarker[J]. Cancer Research on Prevention and Treatment, 2014, 41(07): 839-843. DOI: 10.3971/j.issn.1000-8578.2014.07.033

结直肠癌中microRNA标志物临床诊断价值的研究进展

基金项目: 四川省教育厅青年项目资助课题(11ZB123);四川省卫生厅资助项目(120371)
详细信息
    作者简介:

    裴傲秋(1982-),女,硕士在读,主要从事肿瘤内科研究

    通信作者:

    罗茂,E-mail: luomao20050908@163.com

  • 中图分类号: R730.4;R735. 3

Recent Progress of microRNA as Colorectal Cancer Clinical Biomarker

  • 摘要: 结直肠癌是最常见的消化道恶性肿瘤,其发生、发展及诊疗、预后已成为当前临床研究关注的热点。microRNAs (miRNAs) 是一类内源性的、19~25个碱基长度的小分子非编码RNA,在人体生命活动中具有广泛的调节功能。目前发现,部分miRNAs异常表达与结直肠癌的发生、发展密切相关,提示miRNAs可作为结直肠癌临床早期诊断及预后评估的特异性新型生物标志物。文章综述了miRNAs作为结直肠癌临床早期诊断、预后和治疗结果评估生物标志物的研究进展,揭示结直肠癌miRNAs参与的基因表达调控机制, 展望miRNAs作为结直肠癌新型诊断分子标志物及治疗靶点的广阔临床应用前景。

     

    Abstract: Colorectal cancer is the commonest malignancy. Its occurrence, development, diagnosis and prognosis have become a hot topic in current clinical researches. microRNAs (miRNAs) are an extensive class of endogenous, non-coding, short (19-25 nt) RNA molecules and have the extensive adjustment in human life activities. Recent researches have revealed aberrant expression of miRNAs could contribute to the development and progression of colorectal cancer, indicating that miRNAs could be a novel biomarker in clinical early diagnosis and prognosis evaluation of colorectal cancer. This review focuses on the recent progress of miRNAs in colorectal cancer, including research progress of miRNA as the diagnosis, treatment and prognosis clinical biomarker of colorectal cancer, regulatory mechanisms of miRNAs in colorectal cancer and broad clinical application prospects of miRNAs as the novel colorectal cancer clinical biomarker.

     

  • [1] Corté H, Manceau G, Blons H, et al. MicroRNA and colorectal cancer[J]. Dig Liver Disc,2012,44(3):195-200.
    [2] Meng W, McElroy JP, Volinia S, et al. Comparison of microRNA deep sequencing of matched formalin-fixed paraffin-embedded and fresh frozen cancer tissues[J]. PloS One,2013,8(5):e64393.
    [3] Mao Y, Chen H, Lin Y, et al. microRNA-330 inhibits cell motility by downregulating Sp1 in prostate cancer cells[J]. Oncol Rep,2013,30(1):327-33.
    [4] Dong Y, Wu WK, Wu CW, et al. MicroRNA dysregulation in colorectal cancer: a clinical perspective[J]. Br J Cancer,2011,104 (6) :893-8.
    [5] Aslam MI, Patel M, Singh B, et al. MicroRNA manipulation in colorectal cancer cells: from laboratory to clinical application[J]. J Transl Med,2012,10:128.
    [6] Schee K, Fodstad ?, Flatmark K. MicroRNAs as biomarkers in colorectal cancer[J]. Am J Pathol,2010,177(4):1592-9.
    [7] Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection[J]. Proc Natl Acad Sci U S A,2008,105(30):10513-8.
    [8] Zen K, Zhang CY. Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers[J]. Med Res Rev,2012,32(2):326-48.
    [9] Ng EK, Chong WW, Jin H, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening[J]. Gut,2009,58(10):1375-81.
    [10] Huang Z, Huang D, Ni S, et al. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer[J]. Int J Cancer,2010,127(1):118-26.
    [11] Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases[J]. Cell Res,2008,18(10):997-1006.
    [12] Wang Q, Huang Z, Ni S, et al. Plasma miR-601 and miR-760 are novel biomarkers for the early detection of colorectal cancer[J]. PLoS One,2012,7(9):e44398.
    [13] Luo X, Stock C, Burwinkel B, et al. Identification and evaluation of plasma microRNAs for early detection of colorectal cancer[J]. PLoS One,2013,8(5):e62880.
    [14] Lieberman DA. Clinical practice. Screening for colorectal cancer[J]. N Engl J Med,2009,361(12):1179-87.
    [15] Sali L, Grazzini G, Carozzi F, et al. Screening for colorectal cancer with FOBT, virtual colonoscopy and optical colonoscopy: study protocol for a randomized controlled trial in the Florence district (SAVE study)[J]. Trials,2013,14:74.
    [16] Link A, Balaguer F, Shen Y, et al. Fecal microRNAs as novel biomarkers for colon cancer screening[J]. Cancer Epidemiol Biomarkers Prev,2010,19(7):1766-74.
    [17] Kunte DP, DelaCruz M, Wali RK, et al. Dysregulation of microRNAs in colonic field carcinogenesis: implications for screening[J]. PLoS One,2012,7(9):e45591.
    [18] Ahmed FE, Jeffries CD, Vos PW, et al. Diagnostic microRNA markers for screening sporadic human colon cancer and active ulcerative colitis in stool and tissue[J]. Cancer Genomics Proteomics, 20 09,6(5):281-95.
    [19] Koga Y, Yasunaga M, Takahashi A, et al. MicroRNA expression profiling of exfoliated colonocytes isolated from feces for colorectal cancer screening[J]. Cancer Prev Res (Phila),2010,3(11): 14 35-42.
    [20] Ahlquist DA. Molecular detection of colorectal neoplasia[J]. Gastroenterology,2010,138(6):2127-39.
    [21] Slaby O, Svoboda M, Fabian P, et al. Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer[J]. Oncology,2007, 72 (5-6):397-402.
    [22] Schetter AJ, Leung SY, Sohn JJ, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma[J]. JAMA,2008,299(4):425-36.
    [23] Kulda V, Pesta M, Topolcan O, et al. Relevance of miR-21 and miR-143 expression in tissue samples of colorectal carcinoma and its liver metastases[J]. Cancer Genet Cytogenet,2010,200(2):154- 60.
    [24] Bandrés E, Cubedo E, Agirre X, et al. Identification by Realtime PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues[J]. Mol Cancer,2006,5:29.
    [25] Wang CJ, Zhou ZG, Wang L, et al. Clinicopathological significance of microRNA-31, -143 and -145 expression in colorectal cancer[J]. Dis Markers,2009,26(1):27-34.
    [26] Lanza G, Ferracin M, Gafà R, et al. mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer[J]. Mol Cancer,2007,6:54.
    [27] Schepeler T, Reinert JT, Ostenfeld MS, et al. Diagnostic and prognostic microRNAs in stage Ⅱ colon cancer[J]. Cancer Res,2008,68(15):6416-24.
    [28] Earle JS, Luthra R, Romans A, et al. Association of microRNA expression with microsatellite instability status in colorectal adenocarcinoma[J]. J Mol Diagn,2010,12(4):433-40.
    [29] Yoshida M, Goto M, Kii T, et al. Retrospective study as firstline chemotherapy combined anti-VEGF antibody with fluoropyrimidine for frail patients with unresectable or metastatic colorectal cancer [J]. Digestion,2013,87(1):59-64.
    [30] Nakajima G, Hayashi K, Xi Y, et al. Non-coding MicroRNAs hsalet- 7g and hsa-miR-181b are associated with chemoresponse to S-1 in colon cancer[J]. Cancer Genomics Proteomics,2006,3(5):317-24.
    [31] Song B, Wang Y, Titmus MA, et al. Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells[J]. Mol Cancer,2010,9:96.
    [32] Ragusa M, Majorana A, Statello L, et al. Specific alterations of microRNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment[J]. Mol Cancer Ther,2010,9(12):3396-409.
    [33] Svoboda M, Izakovicova Holla L, Sefr R, et al. Micro-RNAs miR125b and miR137 are frequently upregulated in response to capecitabine chemoradiotherapy of rectal cancer[J]. Int J Oncol,2008,33(3):541-7.
    [34] Dai J, Gu J, Huang M, et al. GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes[J]. Carcinoge nesis,2012,33(7):1327-31.
    [35] Landi D, Gemignani F, Naccarati A, et al. Polymorphisms within micro-RNA-binding sites and risk of sporadic colorectal cancer[J]. Carcinogenesis,2008,29(3):579-84.
    [36] Lee HC, Kim JG, Chae YS, et al. Prognostic impact of microRNArelated gene polymorphisms on survival of patients with colorectal cancer[J]. J Cancer Res Clin Oncol,2010,136(7):1073-8.
    [37] Yang R, Frank B, Hemminki K, et al. SNPs in ultraconserved elements and familial breast cancer risk[J]. Carcinogenesis,2008, 29 (2):351-5.
    [38] Wojcik SE, Rossi S, Shimizu M, et al. Non-codingRNA sequence variations in human chronic lymphocytic leukemia and colorectal cancer[J]. Carcinogenesis,2010,31(2):208-5.
计量
  • 文章访问数:  1444
  • HTML全文浏览量:  472
  • PDF下载量:  1171
  • 被引次数: 0
出版历程
  • 刊出日期:  2014-07-24

目录

    /

    返回文章
    返回
    x 关闭 永久关闭